Lokivetmab Biosimilar Canine Monoclonal Antibody (IL-31) for Research

Cat No.: GMP-Bios-ab-319

Pre-Made Lokivetmab biosimilar, Canine Whole Mab: Anti-IL31 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-319-1mg 1mg 618
GMP-Bios-ab-319-10mg 10mg
GMP-Bios-ab-319-100mg 100mg
GMP-Bios-ab-319-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Lokivetmab biosimilar, Canine Whole Mab: Anti-IL31 therapeutic antibody
INN Name Lokivetmab
TargetIL31
FormatCanine Whole mAb
DerivationCaninized
Species ReactivityCanine
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2014
Year Recommended2015
CompaniesZoetis
Conditions ApprovedCanine atopic dermatitis
Conditions Activena
Conditions Discontinuedna
Development Techna



About target - IL31

1. Protein Interleukin-31

2. Gene IL31

3. Organism Homo sapiens (Human)

Function
Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR (PubMed:15184896).

May function in skin immunity (PubMed:15184896).

Enhances myeloid progenitor cell survival in vitro (By similarity).

Induces RETNLA and serum amyloid A protein expression in macrophages (By similarity).